Skip to content

Person-checked company records fromPerson-checked records $750See a worked exampleHuman review in progress

Talk to sales

KeptIndex

Corcept Therapeutics Inc.

Complete enrollment in the ROSELLA trial

Not delivered by the deadline

AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.

Announced
2 Aug 2023
Due
31 Dec 2023
Checked
1 Oct 2026
  • Deadline
  • Met
  • Late
  • Not met
  • Today

What the company said

“We are on track to complete enrollment by the end of this year”

What we found

Evidence strength A What the grades mean

The company stated in February 2024 that enrollment for the ROSELLA trial was still continuing, indicating the 2023 year-end goal for completion was not met.

  • A
    Corcept Therapeutics Inc. 8-K filed 2024-02-15 Regulatory filing · published 15 Feb 2024 · retrieved 1 Oct 2026 · kept permanently by the SEC · fingerprint 4fc2724c8db1
    “ROSELLA – Pivotal Phase 3 trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer – enrollment continues” ✓ confirmed on the page

Market reaction: the shares moved -6.3% against the S&P 500 over the three sessions around the disclosure (14 Feb 2024 to 20 Feb 2024). What this measures

Checked 1 Oct 2026.

Commitment DNA

The structured record of this commitment. Fields the company did not state are left blank rather than guessed.

Event type
Clinical milestone
Indicative materiality
Medium rules
Action
Complete
Deliverable
ROSELLA trial enrollment
Language
Firm (“will”, “on track to”)
In the company’s control
High
Specificity
High

How this entry was checked

  1. Commitment recordedThe company's words were matched word for word against the filing.
  2. First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
  3. Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
  4. Third check on a negative finding: agreesBecause a negative finding could harm a company if wrong, a stronger model re-read the evidence fully blind and reached the same answer.

Confirmed. This outcome counts towards the company's Kept Score. How verification works

Are you Corcept Therapeutics Inc.? You can publish an official statement next to this entry, free. Add a statement.

Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.

Report an error in this entry Reference: KI-C-2023-CORT-002880 · Corrections policy

The Deadline Report

One email a week: the corporate commitments that came due, which were met, which slipped, and what is due next. Free. Stop any time.

No advertising. We never sell or share your address.